Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.40M | 12.50M | 11.13M | 10.54M | 11.63M | 18.85M |
| Gross Profit | 7.68M | 7.91M | 7.10M | 5.32M | 4.46M | 8.60M |
| EBITDA | -6.08M | -4.63M | -5.44M | -4.93M | -25.67M | -10.69M |
| Net Income | -7.18M | -7.18M | -8.59M | -8.97M | -45.72M | -15.03M |
Balance Sheet | ||||||
| Total Assets | 20.81M | 20.81M | 26.84M | 25.42M | 36.94M | 97.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 1.96M | 6.48M | 3.02M | 7.98M | 44.89M |
| Total Debt | 6.99M | 6.99M | 8.06M | 9.79M | 7.19M | 7.96M |
| Total Liabilities | 14.65M | 14.65M | 19.73M | 15.92M | 19.05M | 39.71M |
| Stockholders Equity | 6.16M | 6.16M | 7.11M | 9.50M | 17.89M | 58.28M |
Cash Flow | ||||||
| Free Cash Flow | -9.39M | -9.39M | 848.00K | -9.79M | -22.39M | -16.77M |
| Operating Cash Flow | -9.33M | -9.33M | 946.00K | -9.64M | -18.04M | -10.89M |
| Investing Cash Flow | -53.00K | -53.00K | -98.00K | 4.31M | -4.36M | -8.33M |
| Financing Cash Flow | 5.28M | 5.28M | 2.63M | 652.00K | -10.92M | 63.27M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$50.59M | -14.73 | -501.54% | ― | ― | 56.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$52.98M | -2.58 | -40.54% | ― | 29.60% | 33.00% | |
45 Neutral | AU$44.17M | -5.81 | -97.79% | ― | ― | 23.85% | |
42 Neutral | AU$182.26M | -16.77 | -111.23% | ― | 12.96% | 40.81% | |
40 Underperform | AU$31.80M | -1.55 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$49.27M | -5.62 | -37.78% | ― | 2.33% | 12.50% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics reported unaudited revenue of US$2.7 million for the quarter to 31 December 2025, down 6.9% on the prior corresponding period, as growth in its flagship FebriDx® product and third‑party CorDx combo tests was unable to fully offset the loss of revenue from its discontinued ViraDx® test. Product revenue came in at US$0.5 million and services revenue held steady at US$2.2 million, supported largely by 12 active customer projects, including the Phase 2 Hologic fFN development program and related IP licensing income. FebriDx® sales rose 4.3 times year-on-year, driven primarily by U.S. demand, while Lumos secured full Medicare reimbursement recognition across the United States and initiated a paediatric study that had enrolled 90 patients by the end of December. The company also advanced its bid for a CLIA waiver for FebriDx®, completing FDA‑requested minor updates to user instructions and a supplemental usability assessment, and remains optimistic that the waiver process is progressing in line with expectations. Lumos ended the quarter with US$3.0 million in cash, down US$1.5 million over three months, and reported an operating cash outflow of US$1.0 million, leaving its undrawn A$5.0 million loan facility as an additional liquidity buffer.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics has secured a follow-on contract with New Jersey-based Aptatek Biosciences to manage an Institutional Review Board-approved multi-centre clinical study aimed at obtaining US Food and Drug Administration clearance for PheCheck, an aptamer-based in-home monitoring device for phenylketonuria (PKU). Valued at about US$0.4 million and scheduled to begin in the second quarter of calendar 2026 for roughly six months, the contract expands Lumos’s role beyond product development into full clinical and regulatory support, including study management, data analysis and preparation of the clinical report for FDA submission, and runs in parallel with ongoing product development and verification work; successful clearance could position Lumos for further revenue from test and reader manufacturing, strengthening its presence in the high-value rare disease diagnostics segment as PheCheck, which already holds FDA Breakthrough Device designation, targets a critical unmet need in at-home PKU monitoring.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics has issued a total of 5,228,863 new fully paid ordinary shares following the exercise of unquoted options by Lind Global Fund II and a company employee, with the shares issued without a prospectus under relevant Corporations Act provisions. In a cleansing notice to the market, the company confirmed it remains compliant with its continuous disclosure and financial reporting obligations, stated there is no excluded information that must be disclosed ahead of its FY 2026 half-year report due by 27 February 2026, and indicated that the expected draft of that report does not contain undisclosed price-sensitive information, helping to maintain regulatory transparency for investors as its capital base modestly expands.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics Holdings Ltd. has applied to the ASX for quotation of 5,228,863 new ordinary fully paid shares, to be traded under its existing ticker LDX. The issuance of these additional securities, arising from the exercise or conversion of existing instruments, modestly expands the company’s listed share capital and may enhance liquidity for investors while signalling ongoing capital management activity.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics is hosting an investor and shareholder webinar titled “Reducing Diagnostic Uncertainty” to showcase how its FebriDx rapid diagnostic test supports evidence-based antibiotic stewardship in outpatient and urgent care settings, particularly during the busy cold and flu season. The session will feature real-world insights from WellStreet Urgent Care, where FebriDx has been integrated into high-volume workflows to improve diagnostic clarity, strengthen stewardship practices, and enhance clinical efficiency, underlining the test’s growing clinical adoption and highlighting Lumos’ positioning in the point-of-care diagnostics market; a recording will be available to all registered participants after the event.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics has entered into a distribution partnership with Interlux Group to expand the availability of its FebriDx® point-of-care diagnostic test in the Baltic region, covering Lithuania, Estonia, and Latvia. This collaboration strengthens Lumos’ presence in Europe, aligning with its strategy to broaden the reach of FebriDx® through established regional partners and enabling quicker adoption in primary care and other healthcare settings.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics Holdings Ltd has issued 35,341 fully paid ordinary shares following the exercise of 42,000 unquoted options by its employees. This issuance was conducted without disclosure under the Corporations Act, and the company confirms its compliance with relevant statutory provisions, indicating a transparent and regulated approach to its operational activities.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 35,341 fully paid ordinary securities on the ASX, following the exercise of options or conversion of other convertible securities. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting its operational capabilities and offering growth opportunities for stakeholders.
Lumos Diagnostics has achieved full U.S. Medicare reimbursement recognition for its FebriDx® test, securing approval from all seven Medicare Administrative Contractors (MACs), including the final approval from National Government Services. This development ensures FebriDx is positioned for broad adoption across the U.S. healthcare system, facilitating access through Medicare Advantage, Medicaid, and private payors. The company will now focus on assisting MACs in developing written policies to streamline reimbursement claims, enhancing clarity and predictability for stakeholders.
Lumos Diagnostics Holdings Ltd. has announced the issuance of 6,007,000 performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 1,323,875 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 31, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially expand its market presence, impacting its operations and positioning within the healthcare diagnostics industry.
Lumos Diagnostics Holdings Ltd has announced a change in the director’s interest, with Doug Ward acquiring 22,000,000 performance rights. This change, approved by shareholders at the company’s 2025 Annual General Meeting, reflects a strategic move to align the interests of the director with the company’s growth objectives, potentially impacting the company’s operations and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the issuance of 22 million unquoted performance rights as part of an employee incentive scheme. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.